Metformin Treatment for Colon Cancer (MECORA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03359681|
Recruitment Status : Recruiting
First Posted : December 2, 2017
Last Update Posted : September 19, 2019
|Condition or disease||Intervention/treatment||Phase|
|Colon Cancer||Drug: Metformin Hydrochloride Drug: Placebo oral capsule||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Perioperative Metformin Treatment for Colon Cancer, a Randomized Trial|
|Actual Study Start Date :||July 10, 2018|
|Estimated Primary Completion Date :||October 2019|
|Estimated Study Completion Date :||November 2019|
Active Comparator: metformin hydrochloride
metformin, encapsulated tablet, 500mg 3 times a day for 30 days.
Drug: Metformin Hydrochloride
metformin 500mg three times a day 20 days before colon cancer surgery and 10 days after.
Other Name: metformin
Placebo Comparator: placebo oral capsule
placebo, encapsulated tablet, 500mg 3 times a day for 30 days.
Drug: Placebo oral capsule
placebo 500mg three times a day 20 days before colon cancer surgery and 10 days after.
Other Name: placebo
- Expression of Ki67 on tumor samples [ Time Frame: colonoscopy (baseline) and at time of operation (after intervention) ]The primary outcome is determination of the difference of the level of proliferation after the intervention (time of surgery) adjusted for the level seen at baseline (time of colonoscopy). This is done using immunohistochemical staining for Ki67 (a marker for proliferation) of biopsies from the tumor. The level of proliferation will be defined as the percentage of tumor nuclei showing Ki67 staining in a specific microscopic field counted at the invasive front.
- Expression of cleaved Caspase-3 on tumor samples [ Time Frame: colonoscopy (baseline) and at time of operation (after intervention) ]Determination of the difference in the level of apoptosis after the intervention (time of surgery) adjusted for the level seen at colonoscopy (baseline). Measured by immunohistochemical staining of tumor samples for cleaved Caspase-3 (marker for apoptosis).
- immunoscore [ Time Frame: time of operation (after the tumor is removed) ]At time of operation biopsies from the core and from the invasive margin of the tumor will be taken. These biopsies are stained for CD3 and CD8 positive lymphocytes and the density of these are measured.
- immunological changes in bloodsamples [ Time Frame: At baseline, day of operation and postoperative day 1, 2 and 10. ]Bloodsamples are taken at time of inclusion, day of operation and postoperative day 1,2 and 10. These are analysed for immunological markers.
- insulin resistance [ Time Frame: At the day of surgery and postoperative day 1 and 2. ]Fasting levels of glucose and insulin are measured at the day of operation (before the operation) and at postoperative day 1 and 2. Insulin resistance is measured using the HOMA-score.
- blood glucose level [ Time Frame: 4 times a day on postoperative day 1 and 2 ]Blood glucose (capillary glucose) level is measured 4 times a day on postoperative day 1 and 2.
- Quality of recovery [ Time Frame: At baseline, postoperative day 1, 2, 10 and 30. ]The patients' subjective feeling of recovery is measured using the Danish version of the Quality of recovery-15 questionnaire. The questionnaire includes 15 questions with the possibility of 0 to 150 points (150 being the best possible quality of recovery)
- cell growth in vitro - proliferation [ Time Frame: At baseline, postoperative day 1 and 10. ]colon cancer cell lines will be grown in vitro in the presence of plasma from the patients. Differences in proliferation between the two groups are measured.
- cell growth in vitro - adhesion [ Time Frame: At baseline, postoperative day 1 and 10. ]colon cancer cell lines will be grown in vitro in the presence of plasma from the patients. Differences in adhesion between the two groups are measured.
- cell growth in vitro - invasion [ Time Frame: At baseline, postoperative day 1 and 10. ]colon cancer cell lines will be grown in vitro in the presence of plasma from the patients. Differences in invasion between the two groups are measured.
- microbiota [ Time Frame: At baseline and the day before surgery ]The microbiota of fecal samples will be analyzed using 16s rRNA analyses
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03359681
|Contact: Emilie P Colov, MD||+45 firstname.lastname@example.org|
|Contact: Ismail Gögenur, MD, DMSc||+45 email@example.com|
|Department of Surgery, Slagelse Hospital||Recruiting|
|Slagelse, Denmark, 4200|
|Contact: Emilie P Colov, MD +45 61335122 firstname.lastname@example.org|
|Principal Investigator:||Emilie P Colov, MD||Department of Surgery, Slagelse Hospital|